All In Biotech

Drug Trial Radar · NCT04047563

Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke

A Prospective, Multicentric, Randomized, Double-blind, Parallel, Phase III Clinical Study to Assess Efficacy of PMZ-1620 Along With Standard Treatment in Patients of Acute Ischemic Stroke

Last checked: Nov 19, 2026Latest source record: Oct 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 158 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

158

Actual

Start

Nov 10, 2019

Primary completion

Feb 10, 2022

Study completion Feb 10, 2022

Sponsor

Lead sponsor
Pharmazz, Inc.Industry
Sponsor type
Industry
First posted
Aug 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 78 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In the present prospective, multicentric, randomized, double-blind, parallel, saline-controlled phase II clinical study; the investigators plan to evaluate the efficacy of sovateltide (IRL-1620 or PMZ-1620) therapy along with standard supportive care in patients of acute ischemic stroke.

Conditions

  • Cerebral Ischemia
  • Cerebral Infarction
  • Stroke, Acute

Interventions

  • Normal Saline along with standard treatmentDrug

    PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. In this arm normal saline along with standard treatment will be given for active comparison.

  • PMZ-1620 (sovateltide) along with standard treatmentDrug

    PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in National Institute of Health Stroke Scale (NIHSS)Time frame: 90 days
  2. Change in modified Rankin Scale (mRS)Time frame: 90 days
  3. Change in Barthel index [BI]Time frame: 90 days
  4. Change in the proportion of ischemic stroke patients with NIHSS score <6Time frame: 90 days
  5. Change in the proportion of ischemic stroke patients with mRS score <2Time frame: 90 days
  6. Change in the proportion of ischemic stroke patients with Barthel index (BI) score >60Time frame: 90 days

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Radiant Superspeciality Hospital

    Amravati, India

  • Post Graduate Institute of Medical Education and Research

    Chandigarh, India

  • Lalitha Superspecialities Hospital

    Guntur, India

  • Dayanand Medical College & Hospital

    Ludhiana, India

  • Department of Neurology, Christian Medical College and Hospital

    Ludhiana, India

  • Sidhu Hospital Pvt. Ltd.

    Ludhiana, India

  • New Era Hospital & Research Institute

    Nagpur, India

  • Chopda Medicare & Research Centre

    Nashik, India

  • All India Institute of Medical Sciences

    New Delhi, India

  • Indian Spinal Injury Centre

    New Delhi, India

  • Pushpanjali Hospital & Research Centre Pvt. Ltd

    Agra, Uttar Pradesh, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.